Latest Content

Urine drug screenings are often misordered and misread, risking stigma and harm; learn immunoassay limits, confirmatory testing basics, and when testing truly helps.

FDA clears a Parkinson disease wearable and fast-tracks ecopipam for pediatric Tourette syndrome, showing advances in neuropsychiatric care.

Learn why varenicline leads smoking cessation products in bipolar disorder, with reassuring safety data and practical strategies when quitting proves difficult.

Remote, home-based tDCS shows modest symptom relief and higher remission in major depression, with generally good safety but burn risks to watch.

A quick recap of the last week in psychiatric news.

FDA approves PET imaging agent for Alzheimer disease tau pathology.

Real‑world inpatient use of xanomeline/trospium shows rapid awakening from negative symptoms in schizophrenia, with response predictors and striking case insights.

Entactogen research targets social anxiety and isolation across diagnoses, pairing “plasticity windows” with psychotherapy amid shifting FDA scrutiny and evolving trial designs.

"...time slowed to the tide’s rhythm and the surf’s roar, each day closed by a Great Horned Owl’s silent fly-by at dusk..."

KINECT-PRO shows Ingrezza eases tardive dyskinesia movements and boosts daily function and quality of life, even across psychiatric diagnoses.

DT120 (lysergide) hits all endpoints in phase 3 GAD trial, cutting anxiety scores with a single dose.

Why modern psychiatry risks missing the person: It's time to revive biopsychosocial, cultural, and spiritual history beyond DSM checklists and EHR bloat.

New data show once-daily CTx-1301 delivers 3 timed dexmethylphenidate releases for faster onset, steadier late-day ADHD coverage, tolerability.